Department of Gastroenterology, Kaiser Permanente San Francisco Medical Center, San Francisco, California; Division of Research, Kaiser Permanente Northern California, Oakland, California.
Department of Gastroenterology, Kaiser Permanente San Francisco Medical Center, San Francisco, California.
Gastroenterology. 2022 Sep;163(3):723-731.e6. doi: 10.1053/j.gastro.2022.05.014. Epub 2022 May 14.
BACKGROUND & AIMS: The COVID-19 pandemic has affected clinical services globally, including colorectal cancer (CRC) screening and diagnostic testing. We investigated the pandemic's impact on fecal immunochemical test (FIT) screening, colonoscopy utilization, and colorectal neoplasia detection across 21 medical centers in a large integrated health care organization.
We performed a retrospective cohort study in Kaiser Permanente Northern California patients ages 18 to 89 years in 2019 and 2020 and measured changes in the numbers of mailed, completed, and positive FITs; colonoscopies; and cases of colorectal neoplasia detected by colonoscopy in 2020 vs 2019.
FIT kit mailings ceased in mid-March through April 2020 but then rebounded and there was an 8.7% increase in kits mailed compared with 2019. With the later mailing of FIT kits, there were 9.0% fewer FITs completed and 10.1% fewer positive tests in 2020 vs 2019. Colonoscopy volumes declined 79.4% in April 2020 compared with April 2019 but recovered to near pre-pandemic volumes in September through December, resulting in a 26.9% decline in total colonoscopies performed in 2020. The number of patients diagnosed by colonoscopy with CRC and advanced adenoma declined by 8.7% and 26.9%, respectively, in 2020 vs 2019.
The pandemic led to fewer FIT screenings and colonoscopies in 2020 vs 2019; however, after the lifting of shelter-in-place orders, FIT screenings exceeded, and colonoscopy volumes nearly reached numbers from those same months in 2019. Overall, there was an 8.7% reduction in CRC cases diagnosed by colonoscopy in 2020. These data may help inform the development of strategies for CRC screening and diagnostic testing during future national emergencies.
COVID-19 大流行对全球临床服务产生了影响,包括结直肠癌(CRC)筛查和诊断检测。我们调查了大流行对粪便免疫化学检测(FIT)筛查、结肠镜检查利用率以及在大型综合医疗保健组织的 21 个医疗中心内检测到的结直肠肿瘤的影响。
我们对 Kaiser Permanente 北加利福尼亚州 2019 年和 2020 年年龄在 18 至 89 岁的患者进行了回顾性队列研究,测量了 2020 年与 2019 年相比,邮寄、完成和阳性 FIT 数量;结肠镜检查数量;以及通过结肠镜检查检测到的结直肠肿瘤数量的变化。
FIT 试剂盒的邮寄在 2020 年 3 月中旬至 4 月停止,但随后反弹,与 2019 年相比,邮寄的试剂盒增加了 8.7%。由于 FIT 试剂盒的后期邮寄,2020 年完成的 FIT 数量减少了 9.0%,阳性测试减少了 10.1%。与 2019 年 4 月相比,2020 年 4 月的结肠镜检查量下降了 79.4%,但在 9 月至 12 月期间恢复到接近大流行前的水平,导致 2020 年总结肠镜检查量下降了 26.9%。2020 年通过结肠镜检查诊断为 CRC 和高级腺瘤的患者数量分别下降了 8.7%和 26.9%。
与 2019 年相比,2020 年的 FIT 筛查和结肠镜检查数量减少;然而,在解除就地避难令后,FIT 筛查量超过,结肠镜检查量几乎达到 2019 年同期的水平。总体而言,2020 年通过结肠镜检查诊断的 CRC 病例减少了 8.7%。这些数据可能有助于为未来的国家紧急情况制定 CRC 筛查和诊断检测策略提供信息。